- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01362010
Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients
Pilot, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study, to Evaluate the Tolerability and Safety of FXFM244 Antibiotic Foam and to Monitor Its Clinical Effect in Acne Vulgaris Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase IIa prospective, multicenter, randomized, double blind, placebo controlled, parallel group, dose range finding clinical study to evaluate the safety, tolerability and efficacy of Minocycline Foam 1% and 4% for the treatment of Acne Vulgaris.
The study consists of a screening / baseline visit, a treatment period where patients will be treated topically on the facial skin areas affected by acne twice daily for 12 weeks, followed by a post-treatment follow up visit 4 weeks after end of treatment. The first dose will be applied in the presence of the study investigator or his assignee. Subsequent applications will be made by the patients.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Netanya, Israel
- Lev Yasmin Clinic
-
Tel-Aviv, Israel
- Sourasky Medical Center
-
Tel-Aviv, Israel
- Tel-Nordau Clalit health services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A clinical diagnosis of Acne Vulgaris with facial involvement.
- A minimum of 20 but not more than 50 inflammatory lesions on the face (papules and/ or pustules).
- A minimum of 25 but not more than 100 non-inflammatory lesions on the face (opened and/or closed comedones).
- No significant nodulocystic acne on the face (≤ 2 lesions).
- A score of >3 (Moderate) on the Investigator's Global Assessment Scale.
- Patient is male or female between the ages of 12 to 25.
- No known medical conditions that, in the Investigator's opinion could interfere with study participation.
- Patient is willing to refrain from use of all other topical acne medications or antibiotics during the study.
- Patient is willing to refrain from use of moisturizers, new brands of make-up, creams, lotions, powders or any topical product other than the assigned treatment to the treatment area.
- Patient is willing and able to comply with all requirement of the protocol.
- Patient is willing and able to give written informed consent prior to participation in the study.
- If female of childbearing potential, willing to use an acceptable form of birth control during the study. Use of oral contraceptives must remain constant within 3 month prior to baseline and throughout the study.
Exclusion Criteria:
- Acne Conglobata, Acne Fulminas, secondary acne (chloracne, drug induced acne), or severe acne requiring systemic treatment.
- Presence of any facial skin condition that would interfere with the diagnosis or assessment of Acne Vulgaris (e.g. rosacea, dermatitis, psoriasis, squamos cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis).
- Excessive facial hair (beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of Acne Vulgaris.
- Known or suspected hypersensitivity to Minocycline or any of the excipients in the Study Medication.
- Concomitant medication:
- Use within 6 month prior to baseline of topical retinoids, oral retinoids (Accutane®) or therapeutic Protocol No. FX2010-03 Foamix Ltd. Page 8 of 28 Confidential Ver: 02 Oct-31-2011 vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
- Use of systemic steroids, systemic antibiotics, systemic treatment for Acne Vulgaris, systemic antiinflammatory agents within 4 weeks prior to baseline.
- Use of topical steroids, α-hydroxy/glycolic acid, benzoyl peroxide, topical antibiotics, topical treatment for Acne Vulgaris, topical anti-inflammatory agents within 2 weeks prior to baseline.
- Use for less than 3 month prior to baseline of estrogens or change in oral contraceptives therapy within less than 3 month prior to baseline;
- Use on the face of: cryodestruction or chemodestruction, dermabrasion, photodynamic therapy, acne surgery, intralesional steroids or X-ray therapy within 4 weeks prior to baseline..
- Alcohol or drug abuse, according to assessment by the investigator.
- Use of another investigational drug within 30 days prior to baseline.
- Pregnant or lactating women.
- Use of tanning booths, sunbathing, or excessive exposure to the sun should be prohibited during the study.
- Participation in clinical trial in the previous month.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Topical Minocycline Foam FXFM244 - 4%
Active ingredient: Minocycline Concentration: 4% Route: Topical Dosage schedule: Once daily, evening.
|
Topically applied once a day.
Other Names:
|
Experimental: Topical Minocycline Foam FXFM244 - 1%
Active ingredient: Minocycline Concentration: 1% Route: Topical Dosage schedule: Once daily, evening.
|
Topically applied once a day.
Other Names:
|
Placebo Comparator: Placebo foam
Active ingredient: None Route: Topical Dosage schedule: Once daily, evening
|
Topically applied once a day.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease in lesions count
Time Frame: 12 weeks
|
The change in lesion count (inflammatory, non-inflammatory, and total) after 12 weeks of treatment compared to baseline
|
12 weeks
|
Investigator global assessment
Time Frame: 12 weeks
|
Physician's Global Improvement Assessment
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
% change in lesions count
Time Frame: 12 weeks
|
The % change in lesions count (inflammatory, non-inflammatory, and total) after 12 weeks of treatment compared to baseline
|
12 weeks
|
Global assessment of improvement by photographs
Time Frame: 12 weeks
|
The photographs will assist in comparison of efficacy at subsequent visits compared to baseline
|
12 weeks
|
Subject-reported outcome assessment
Time Frame: 12 weeks
|
12 weeks
|
|
Subjects safety
Time Frame: 12 weeks
|
safety parameters will be assessed by
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joseph Shiri, Prof., Clalit Health Services
- Principal Investigator: Eli Sprecher, MD, Sourasky Medical Center
- Principal Investigator: Avner Shemer, Prof., Lev Yasmin clinic, Netanya, Israel
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FX2010-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Nexgen Dermatologics, Inc.Unknown
-
PollogenLumenis Be Ltd.RecruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.Active, not recruitingInflammatory Acne VulgarisUnited States
-
Assiut UniversityCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
Clinical Trials on Topical Minocycline Foam FXFM244
-
Vyne Therapeutics Inc.Terminated
-
Vyne Therapeutics Inc.Completed
-
Edward Lain, MDVyne Therapeutics Inc.CompletedAcne VulgarisUnited States
-
Vyne Therapeutics Inc.CompletedRosacea | Papulopustular RosaceaGermany
-
Vyne Therapeutics Inc.Premier Research Group plcCompletedFacial Papulopustular RosaceaUnited States
-
Vyne Therapeutics Inc.Premier Research Group plcCompletedFacial Papulopustular RosaceaUnited States
-
Skin Sciences, PLLCUnknownPlaque PsoriasisUnited States
-
Vyne Therapeutics Inc.CompletedAcne VulgarisUnited States, Dominican Republic
-
Vyne Therapeutics Inc.CompletedAcne VulgarisUnited States, Dominican Republic
-
Hovione Scientia LimitedCompletedMeibomian Gland Dysfunction | MGD-Meibomian Gland DysfunctionUnited States